Clinical and Translational Imaging - Editor's Pick on PSMA and prostate cancer in diagnosis and therapy
Please find below the latest articles published on this topic.
Carrilho Vaz, S., Silva, Â., Oliveira, C. et al.
Impact of PSMA PET/CT in prostate cancer patient’s clinical management: a pictorial essay of interesting cases with histologic confirmation.
Clin Transl Imaging 8, 207–226 (2020).
https://doi.org/10.1007/s40336-020-00372-2
Okarvi, S.M.
Recent developments of prostate-specific membrane antigen (PSMA)-specific radiopharmaceuticals for precise imaging and therapy of prostate cancer: an overview.
Clin Transl Imaging 7, 189–208 (2019).
https://doi.org/10.1007/s40336-019-00326-3
Ceci, F., Fanti, S.
PSMA-PET/CT imaging in prostate cancer: why and when.
Clin Transl Imaging 7, 377–379 (2019).
https://doi.org/10.1007/s40336-019-00348-x
Carpanese, D., Zorz, A., Evangelista, L. et al.
Targeting prostate cancer with the anti-PSMA scFvD2B: a theranostic promise for nuclear medicine.
Clin Transl Imaging 7, 295–301 (2019).
https://doi.org/10.1007/s40336-019-00337-0
von Eyben, F.E., Baumann, G.S. & Baum, R.P.
PSMA diagnostics and treatments of prostate cancer become mature.
Clin Transl Imaging 6, 145–148 (2018).
https://doi.org/10.1007/s40336-018-0270-2
Pozzo, L., Monteiro, L.R., Cerci, J.J. et al.
HTA in nuclear medicine: [68Ga]PSMA PET/CT for patients with prostate cancer.
Clin Transl Imaging 7, 7–20 (2019).
https://doi.org/10.1007/s40336-019-00313-8
Kairemo, K., Joensuu, T.
Lu-177-PSMA treatment for metastatic prostate cancer: case examples of major responses.
Clin Transl Imaging 6, 223–237 (2018).
https://doi.org/10.1007/s40336-018-0274-y